bioAffinity Technologies, Inc.
BIAF · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $2 | $2 |
| % Growth | 13.9% | -31.5% | -16% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $2 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 27% | 19.9% | 26.2% | 22.3% |
| R&D Expenses | $0 | $0 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $3 | $3 |
| Operating Income | -$2 | -$3 | -$3 | -$3 |
| % Margin | -158.6% | -198.2% | -141.7% | -133.5% |
| Other Income/Exp. Net | -$3 | -$2 | -$0 | -$0 |
| Pre-Tax Income | -$5 | -$4 | -$3 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$4 | -$3 | -$3 |
| % Margin | -349.3% | -319.9% | -143.5% | -134.4% |
| EPS | -4.74 | -5.07 | -4.8 | -6.3 |
| % Growth | 6.5% | -5.6% | 23.8% | – |
| EPS Diluted | -4.74 | -5.07 | -4.8 | -6 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 0 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$4 | -$2 | -$3 |
| % Margin | -340.9% | -307.9% | -133.9% | -126.3% |